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1. Introduction 
In spite of extensive studies there is still little 
known about the molecular structure of the mem- 
brane-bound adenylate cyclase complex [ 1,2]. Never- 
theless, there are some indications on the involvement 
of sulfhydryl and disulfide groups in the enzyme activ- 
ity. It has been shown that several thiol group reagents 
inhibit adenylate cyclase [3-S]. Furthermore, 50% 
loss of adenylate cyclase activity with mercapto- 
‘ethanol points out to the role of disulfide groups in 
the enzyme complex 191. Similar results about the 
importance of vicinal dithiol groups for guanylate 
cyclase have been reported [IO]. 
In contrast to the above inhibition of adenylate 
cyclase by agents affecting either -SH or S--S groups, 
the activation of spleen adenylate cyclase by mercapto- 
ethanolamine and its respective disulfide (cystamine) 
has been demonstrated here. 
2. Materials and methods 
[U-‘“Cl ATP, spec. act. 573 mCi~mmo1, was obtained 
from Radiochemical Centre, Amersham. ATP and 
adenosine 3’,.5’-cyclic monophosphate [CAMP] were 
purchased from Calbiochem. Phosphoenoiopyruvate, 
pyruvate kinase, 2-mercaptoethylamine-HCl, di- 
(aminoethyl)disulfide (cystamine) and bovine serum 
albumin Cohn fraction V were obtained from Koch- 
Light. Polyethyleneimine was purchased from British 
Drug Houses. Cellulose MN 300 was obtained from 
Machery-Nagel. PEI-cellulose was prepared by the 
method in [ 111. PPO and POPOP were from Fluka. 
CFW male mice, 3 months, were killed by cervical 
dislocation. The spleens were im~nediately removed, 
weighed and washed with 10 mM ice-cold Tris-HCl 
buffer (pH 7.5). Homogenization was carried out in 
5 vol. same buffer in an all-glass homogenizer and the 
homogenate was strained through 4 layers of gause. 
Mercaptoethanolamine and cystamine dissolved in 
10 mM Tris-NC1 (pH 7.5) were incubated with the 
homogenate (8- 12 mg/ml) in a shaking water bath for 
10 min at 37’C. Then 50 ,ul portions from each sample 
were taken to the adenylate cyclase reaction mixture. 
Adenylate cyciase activity was determ~ed follow- 
ing the conversion of [14C]ATP to cyclic [r4C]AMP 
as detailed in [ 121. The assay media contained 0.4 mM 
[U-14C]ATP (16 @X/pmol), 1 mM CAMP, an ATP- 
regenerating system (20 mM phosphenolpyruvate, 
20 pg pyruvate kinase, 5 mM KCl), 40 mM Tris-HCl 
buffer (pH 8.2) and 0.3-0.6 mg of spleen homogenate 
protein in final vol. 150 pl. 
The reaction, initiated by the addition of the 
homogenate, was run at 37°C for 10 min, and was 
stopped by 3 min boiling. The cAMP formed was 
isolated by thin-layer chromatography on PEI-cellulose 
with ethanol~O.5 M aInmonium acetate (5:2) as the 
developing solvent. The radioactivity of CAMP was 
counted in Bray’s solution [ 131 using a Nuclear Chicago 
Mark I liquid scintillation radiometer. 
Protein was determined by the Lowry method [ 141. 
3. Results and discussion 
The effects of mercaptoethanolamine and cystamine 
in vitro on adenylate cyclase activity of the mouse 
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Table I 
Activation of adenylate cyclase of the mouse spleen 
homogenate by mercaptoethanolammc and cystamme 
-__ 
Addition Spec. act. 
m M (pm01 cAMP/mg prot./ 
min) 
____- 
None 18.2 t 1.4 
Mercaptocthanol- 
ammc 0.1 41.4 + 6.1 
1.0 46.2 * 4.2 
10.0 37.5 + 2.2 
Cystamine 0.1 38.8 f 3.1 
1.0 38.4 * 4.9 
10.0 30.3 i 2.2 
Spleen homogenate xvas preincubated at 37” for 10 min m 
the presence of mercaptocthanolammc and cystamine as 
shown. Adenylate cyclase activity was measured as in sec- 
tion 2. Results are expressed as mean r SD of four dcter- 
mindtlons. 
spleen homogenate are shown in table 1. Both mer- 
csptoethanolamine and cystamine were found to 
increase the enzyme activity by l-fold. The activation 
occurred at the homogenate protein > 7 mg/ml. It 
might indicate that the activating effect of mercapto- 
ethanolamine and cystamme depended on its ratio to 
the pool of reactive cysteine protein residues during 
the treatment. 
It is well known that mercaptoethanolamine forms 
mixed disulfides by reacting with protein disultide 
groups. Cystamine, on the other hand. reacts with 
disulfide as well as with thiol groups. The same in flu- 
ence of both agents on the adenylate activity strongly 
suggests their direct interaction with dlsultide groups 
of the enzyme complex leading to the observed 
enzyme activation. It is worth emphasizmg that while 
spleen adenylste cyclase activity was enhanced by 
cystamine brain adenylate cyclase was inhibited by 
DTNB (dithiobisnitrobenzoic acid), another disulfide 
compound but not forming mixed disulfides [5]. 
At present it is difficult to answer whether the 
noticed effects were due to direct interaction of 
mercaptoethanolamine and cystamine with the 
enzyme itself or with any regulatory protein of the 
enzyme complex. Nevertheless, the results seem to 
indicate the role of S-S bridges in adenylate cyclase 
complex. Thus. the activation of spleen adenylate 
cyclase following the i.p. administration of mcrcapto- 
ethanolamine and cystamine, described in [12,15], 
may also be considered to result from formation of 
mixed disulfides with critical S-S groups of the 
enzyme complex. 
Acknowledgement 
The authors thank Mrs Anna Sztyklel for her 
skilled technical assistance. 
References 
[ 1) Perkins, J. P. (1973) Adv. Cyclic Nucl. Res. 3. l-64. 
[2] Rodbell, M., Lm, M. C.. Salomon, Y.. Londos, C., 
Harwood, J. P., Martin, B. R., Rendcll. M. and Berman, 
M. (1975) Adv. Cyclic Nucl. Res. 5. 3-29. 
[3] Khandelwal, R. L. and Hamilton. I. R. (1971) J. Biol. 
Chem. 246,3297-3304. 
[4] Pohl. S. L.. Bnnbaumer. L. and Rodbcll. M. (1971) J. 
Biol. Chem. 246. 1849-1856. 
[S] l:errendelli, J. A., Johnson, E. M., jr, Chang M. M. and 
Needleman, P. (1973) Biochem. Pharmacol. 22. 
3133-3136. 
[6] Storm, D. R. and Gunsalus, R P. (1974) Nature 250, 
778-779. 
[7] Mauler, P. and Hanoune, J. (1975) Eur. J. Biochem. 
59.593-599. 
[8] Spiegel. A. hl.. Brown. E. M. and Aurbach. C. D. (1976) 
J. Cyclic Nucl. Rcs. 2, 393-404. 
[9] Birnbaumcr. L., Duran. .I. 11., Nakahara. T. and 
Kaumann. A. J. (1977) in: Mammalian Cell Membranes 
(Jamxson,G.A.andRobmson.D.M.eds)pp. 105-150, 
Buttcrworths. London. 
[lo] Craven, P. A. and DeRubertis. t.. R. (1978) Blochim. 
Biophys. Acta 524, 231-244. 
[ 111 Randerath, I<. and Rdnderath, E. (1967) hlcthods 
Enzymol. 12A. 323-347. 
1121 Soktysiak-Pawluczuk, D. and Bitny-Szlachto, S. (1978) 
Acta Polon. Pharm. 35, 259-262. 
[13] Bray. G. A. (1960) Anal. Biochem. 1,279-285. 
[ 141 Lowry, 0. II., Rosebrough, N. J. Farr, A. L. and 
Randall. R. J. (1951) J. Biol. Chem. 193, 265-276. 
[15] S&yslak-Pawtucauk, D. and Bitny-Szlachto, S. (1976) 
Int. J. Radiat. Blol. 29. 549-553. 
174 
